SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society, Inc., 2002.
  • 2
    Yi PI, Coleman M, Saltz L, et al. Chemotherapy for large cell lymphoma: a status update. Semin Oncol. 1990; 17: 6073.
  • 3
    The Non-Hodgkin's Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma. Ann Oncol. 1997; 8: 973978.
  • 4
    Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000; 5: 224237.
  • 5
    Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2001; 19: 389397.
  • 6
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235242.
  • 7
    Boccuti C, Moon M. Comparing Medicare and private insurers: growth rates in spending over three decades. Health Aff (Millwood). 2003; 22: 230237.
  • 8
    Ubel P, Hirth R, Chernew M, Fendrick A. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003; 163: 16371641.
  • 9
    Garber AM. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood). 2004 (Suppl Web Exclusives): W4-284W4-296.
  • 10
    Oken M, Creech R, Tormey D. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649655.
  • 11
    Stockerl-Goldstein KE, Reddy SA, Horning SF, et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with “poor” mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant. 2000; 6: 506512.
  • 12
    Freedman AS, Friedburg JW. Treatment of highly aggressive non-Hodgkin's lymphomas. 2005 UpToDate® online 12.3. Available from URL: http://www.uptodate.com [accessed December 13, 2004].
  • 13
    [no authors listed]. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329: 987994.
  • 14
    Physican's Desk Reference Staff. 2003 Drug topics (R) red book. Montvale, NJ: Thomson PDR, 2003.
  • 15
    Weeks J, Yeap B, Canellos G, Shipp M. Value of follow-up procedures in patients with large cell lymphoma who achieve a complete remission. J Clin Oncol. 1991; 9: 11961203.
  • 16
    Waters T, Bennett C, Pajeau T, et al. Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know? Bone Marrow Transplant. 1998; 21: 641650.
  • 17
    Rizzo J, Vogelsang G, Krumm S, Frink B, Mock V, Bass E. Outpatient-based bone marrow transplantation for haematologic malignancies: Cost saving or cost shifting? J Clin Oncol. 1999; 17: 28112818.
  • 18
    Hoover D, Crystal S, Kumar R. Medical expenditures during the last year of life: findings from the 1992–1996 Medicare Current Beneficiary Survey. Health Serv Res. 2002; 37: 16251642.
  • 19
    Hogan C, Lunney J, Gabel J, Lynn J. Medicare beneficiaries' costs of care in the last year of life. Health Aff (Millwood). 2001; 20: 188195.
  • 20
    Stabler B, Berkowitz LR, Schell MJ, et al. Quality-of-life (QoL) in patients treated with rituximab as a single agent [abstract 2693]. Presented at the 2002 Annual Meeting of the American Society of Clinical Oncology. Available from URL: http://www.asco.org/ac/1,1003,_12-002643-00_18-0016-00_19-002639,00asp [accessed December 13, 2004].
  • 21
    Doorduijn J, Buijt I, Uyl-de Groot C, van der Holt B, Sonneveld P. Quality of life (QOL) in elderly patients with aggressive non-Hodgkin's lymphoma (NHL) treated with CHOP [abstract 1803]. Blood. 2001; 98: 430a.
  • 22
    Mackie M. Hodgkin's disease and non-Hodgkin's lymphoma. In: BlackR, StocktonD, editors, for the Scottish Executive Health Department. Cancer scenarios: an aid to planning cancer services in Scotland in the next decade. Edinburgh: The Scottish Executive, 2001. Chapter sections in HTML format available from URL: http://www.show.scot.nhs.uk/sehd/publications/csatp/csatp-20.htm [accessed December 13, 2004].
  • 23
    Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health. 2003; 6: 917.
  • 24
    Lipscomb J, Weinstein M, Torrence G. Time preference. In: GoldMR, SiegellJE, RussellL, WeinsteinM, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 214246.
  • 25
    Earle C, Chapman R, Baker C, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000; 18: 33023317.
  • 26
    Beard SM, Lorigan PC, Sampson FC. The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Br J Cancer. 2000; 82: 8184.
  • 27
    Kattan MW, Inoue Y, Giles FJ, et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med. 1996; 125: 541548.
  • 28
    Nord E, Wisloff F, Hjorth M, Westin J. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial. Pharmacoeconomics. 1997; 12: 89103.
  • 29
    Norum J, Angelsen V, Wist E, Olsen JA. Treatment costs in Hodgkin's disease: a cost-utility analysis. Eur J Cancer. 1996; 32A: 15101517.
  • 30
    Uyl-de Groot C, Hagenbeek A, Verdonck L. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant. 1995; 16: 463470.
  • 31
    Jagannath S, Vesole DH, Zhang M, et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant. 1997; 20: 445450.
  • 32
    Weeks J, Tierney M, Weinstein MC. Cost-effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991; 325: 8186.
  • 33
    Armitage J, Cheson B. Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol. 1988; 6: 13351347.
  • 34
    Coiffier B, Herbrecht R, Tilly H et al. for GELA. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with an analysis according to co-morbidity factors. Presented at the 2003 Annual Meeting of the American Society of Clinical Oncology. Abstract and Microsoft® Powerpoint slides available from URL: http://www.asco.org/ac/1,1003,_12-002511-00_18-0023-00_19-001570,00.asp [accessed December 13, 2004].
  • 35
    Edelman M, Meyers F, Siegel D. The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis. J Gen Intern Med. 1997; 12: 318331.
  • 36
    Report on State of the Art in Blood and Marrow Transplantation: The 2003 BMT summary slides with guide. From the Center for International Blood and Marrow Transplant Research. Newsletter 2004; 10(2). PDF and Microsoft® Powerpoint slides available from URL: http://www.ibmtr.org/newsletter/newsletter_sums.html [accessed December 13, 2004].
  • 37
    Weinstein M, Siegel J, Gold M, Kamlet M, Russell L. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276: 12531258.